

The Bethesda System for Reporting Thyroid Cytopathology

Edmund S. Cibas¹ and Syed Z. Ali²

Objective: To address terminology and other issues related to thyroid fine-needle aspiration (FNA), the National Cancer Institute (NCI) hosted The NCI Thyroid FNA State of the Science Conference. The conclusions regarding terminology and morphologic criteria from the NCI meeting led to the Bethesda Thyroid Atlas Project and form the framework for the Bethesda System for Reporting Thyroid Cytopathology.

Design: Participants of the Atlas Project were selected from among the committee members of the NCI FNA State of the Science Conference and other participants at the live conference. The terminology framework was based on a literature search of English language publications dating back to 1995 using PubMed as the search engine; online forum discussions (<http://thyroidfna.cancer.gov/forums/default.aspx>); and formal interdisciplinary discussions held on October 22 and 23, 2007, in Bethesda, MD.

Main Outcome: For clarity of communication, the Bethesda System for Reporting Thyroid Cytopathology recommends that each report begin with one of the six general diagnostic categories. Each of the categories has an implied cancer risk that links it to an appropriate clinical management guideline.

Conclusions: The project participants hope that the adoption of this framework will facilitate communication among cytopathologists, endocrinologists, surgeons, and radiologists; facilitate cytologic–histologic correlation for thyroid diseases; facilitate research into the understanding of thyroid diseases; and allow easy and reliable sharing of data from different laboratories for national and international collaborative studies.

Introduction

FINE-NEEDLE ASPIRATION (FNA) plays an essential role in the evaluation of the euthyroid patient with a thyroid nodule. It reduces the rate of unnecessary thyroid surgery for patients with benign nodules and appropriately triages patients with thyroid cancer to appropriate surgery. Before the routine use of thyroid FNA, the percentage of surgically resected thyroid nodules that were malignant was 14% (1). With current thyroid FNA practice, the percentage of resected nodules that are malignant surpasses 50% (2).

It is critical that the cytopathologist communicate thyroid FNA interpretations to the referring physician in terms that are succinct, unambiguous, and clinically helpful. Historically, terminology for thyroid FNA has varied significantly from one laboratory to another, creating confusion in some instances and hindering the sharing of clinically meaningful data among multiple institutions.

To address terminology and other issues related to thyroid FNA, the National Cancer Institute (NCI) hosted “The NCI Thyroid Fine Needle Aspiration State of the Science Conference.” The meeting was organized by Andrea Abati, M.D.,

and took place on October 22 and 23, 2007, in Bethesda, MD. Edmund S. Cibas, M.D., and Susan J. Mandel, M.D., M.P.H., served as moderators. Zubair W. Baloch, M.D., Ph.D., served as Chair of the Terminology and Morphologic Criteria committee. Preparations for the conference began 18 months earlier with the designation of a steering committee, coordination with cosponsoring organizations, and the establishment of a dedicated, permanent Web site.

Literature reviews were limited to English language publications dating back to 1995, using PubMed as the search engine, with key words determined by the committee members. The first draft of the committees’ summary documents was posted on the Web site and open for online discussion from May 1 to June 30, 2007. There were several subsequent drafts and online discussion periods (August 15–September 30, 2007, and November 30–December 15, 2007). The documents underwent revision after each comment period before reposting on the Web. The 2-day “live” conference in October 2007, attended by 154 registrants comprised of pathologists, endocrinologists, surgeons, and radiologists, gave the committees an in-depth opportunity to present their conclusions and debate controversial areas.

By mutual agreement among the authors and editors of their respective journals, this work is being published jointly in *Thyroid* and the *American Journal of Clinical Pathology*.

¹Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts.

²Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.

The Bethesda System for Reporting Thyroid Cytopathology

The NCI conference participants acknowledged the importance of developing an uniform terminology for reporting thyroid FNA results. An inspiration for the thyroid proposal was the Bethesda System for reporting cervical cytology interpretations, first developed at an NCI workshop in 1988 and widely adopted in the United States for reporting Pap test results. It is expected that the many benefits, clinical and investigational, of the Bethesda cervical terminology will also apply to the Bethesda thyroid terminology. A uniform reporting system for thyroid FNA will

- facilitate effective communication among cytopathologists, endocrinologists, surgeons, radiologists, and other health care providers;
- facilitate cytologic-histologic correlation for thyroid diseases;
- facilitate research into the epidemiology, molecular biology, pathology, and diagnosis of thyroid diseases, particularly neoplasia;
- allow easy and reliable sharing of data from different laboratories for national and international collaborative studies.

An online atlas of illustrations of the Bethesda diagnostic categories is currently being assembled on the Papanicolaou Society Web site under the direction of Syed Ali, M.D., Chair of the Online Atlas Committee. A print atlas, with over 40 contributing authors (see end of text), is in press (3).

It was apparent from the discussions at the conference and the Web postings that the primary purpose of terminology is clarity of communication. The interpretation should provide clinically relevant information that will assist the referring physician in the management of the patient. The terms for reporting results should have an implied (or explicit) risk of malignancy upon which recommendations for patient management (e.g., annual follow-up, repeat FNA, surgical lobectomy, and near total thyroidectomy) can be based.

The discussions and conclusions regarding terminology and morphologic criteria from the NCI meeting, summarized in the publications by Baloch *et al.* (4,5), form the framework for the terminology presented here and in atlas form (3). It is intended as a flexible framework that can be modified to suit the needs of the particular laboratory and the patients it serves.

Format of the Report

For clarity of communication, the Bethesda System for Reporting Thyroid Cytopathology recommends that each report begin with a general diagnostic category. The six general diagnostic categories are shown in upper case in Table 1. Some categories have two alternative names; a consensus was not reached at the NCI conference on a single name for these categories. Each of the categories has an implied cancer risk (ranging from 0% to 3% for the Benign category to virtually 100% for the Malignant category) that links it to a rational clinical management guideline (Table 2).

For some of the general categories, some degree of subcategorization can be informative and is often appropriate; recommended terminology is shown in Table 1. Additional descriptive comments (beyond such subcategorization) are optional and left to the discretion of the cytopathologist.

TABLE 1. THE BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: RECOMMENDED DIAGNOSTIC CATEGORIES

I. NONDIAGNOSTIC or UNSATISFACTORY
Cyst fluid only
Virtually acellular specimen
Other (obscuring blood, clotting artifact, etc.)
II. BENIGN
Consistent with a benign follicular nodule (includes adenomatoid nodule, colloid nodule, etc.)
Consistent with lymphocytic (Hashimoto) thyroiditis in the proper clinical context
Consistent with granulomatous (subacute) thyroiditis
Other
III. ATYPIA OF UNDETERMINED SIGNIFICANCE or FOLLICULAR LESION OF UNDETERMINED SIGNIFICANCE
IV. FOLLICULAR NEOPLASM or SUSPICIOUS FOR A FOLLICULAR NEOPLASM
Specify if Hürthle cell (oncocyctic) type
V. SUSPICIOUS FOR MALIGNANCY
Suspicious for papillary carcinoma
Suspicious for medullary carcinoma
Suspicious for metastatic carcinoma
Suspicious for lymphoma
Other
VI. MALIGNANT
Papillary thyroid carcinoma
Poorly differentiated carcinoma
Medullary thyroid carcinoma
Undifferentiated (anaplastic) carcinoma
Squamous cell carcinoma
Carcinoma with mixed features (specify)
Metastatic carcinoma
Non-Hodgkin's lymphoma
Other

From Ali and Cibas (3). With kind permission from Springer Science and Business Media.

Notes and recommendations are not required but can be useful in certain circumstances. Some laboratories, for example, may wish to state the risk of malignancy associated with the general category, based on its own data or that found in the literature (Table 2).

Nondiagnostic or unsatisfactory

Every thyroid FNA must be evaluated for adequacy. Inadequate samples are reported as "Nondiagnostic (ND)" or "Unsatisfactory (UNS)." This category applies to specimens that are unsatisfactory due to obscuring blood, overly thick smears, air drying of alcohol-fixed smears, or an inadequate number of follicular cells. For a thyroid FNA specimen to be satisfactory for evaluation (and benign), at least six groups of benign follicular cells are required, each group composed of at least 10 cells (6,7). The minimum size requirement for the groups allows one to determine (by the evenness of the nuclear spacing) whether or not they represent fragments of macrofollicles.

There are several exceptions to the numerical requirement of benign follicular cells. Any specimen that contains abundant

TABLE 2. THE BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: IMPLIED RISK OF MALIGNANCY AND RECOMMENDED CLINICAL MANAGEMENT

<i>Diagnostic category</i>	<i>Risk of malignancy (%)</i>	<i>Usual management^a</i>
Nondiagnostic or unsatisfactory	1–4	Repeat FNA with ultrasound guidance
Benign	0–3	Clinical follow-up
Atypia of undetermined significance or follicular lesion of undetermined significance	~5–15 ^b	Repeat FNA
Follicular neoplasm or suspicious for a follicular neoplasm	15–30	Surgical lobectomy
Suspicious for malignancy	60–75	Near-total thyroidectomy or surgical lobectomy ^c
Malignant	97–99	Near-total thyroidectomy ^c

Modified from Ali and Cibas (3). With kind permission from Springer Science and Business Media.

^aActual management may depend on other factors (e.g., clinical and sonographic) besides the FNA interpretation.

^bEstimate extrapolated from histopathologic data from patients with “repeated atypicals.”

^cIn the case of “suspicious for metastatic tumor” or a “malignant” interpretation indicating metastatic tumor rather than a primary thyroid malignancy, surgery may not be indicated.

colloid is considered adequate (and benign), even if six groups of follicular cells are not identified: a sparsely cellular specimen with abundant colloid is, by implication, a predominantly macrofollicular nodule and therefore almost certainly benign. Whenever a specific diagnosis (e.g., lymphocytic thyroiditis) can be rendered, and whenever there is any atypia, the specimen is, by definition, adequate for evaluation. ND/UNS results occur in 2–20% of cases but ideally should be limited to no more than 10% of thyroid FNAs, excluding samples comprised exclusively of macrophages (8–10).

Specimens that consist only of cyst contents (macrophages) are problematic. Many laboratories have traditionally considered a macrophages-only sample unsatisfactory and included them in the ND/UNS category, with the understanding that, because the parenchyma of the nodule has not been sampled, one cannot exclude a cystic papillary carcinoma. In such laboratories, “macrophages-only” often constituted the great majority of ND/UNS cases, with rates that ranged from 15% to 30% (2,9,11,12). Other laboratories considered the risk of a false-negative result negligible and reported macrophages-only as benign (10,11). At the 2007 NCI Conference, it was decided that cyst fluid-only (CFO) cases should be considered a clearly identified subset of ND/UNS. The significance (and clinical value) of a CFO result depends in large part on sonographic correlation. If the nodule is almost entirely cystic, with no worrisome sonographic features, an endocrinologist might proceed as if the CFO were a benign result. On the other hand, it might be clinically equivalent to an ND result if the sonographic features are worrisome and the endocrinologist is not convinced that the sample is representative. In a study that segregated CFO cases and analyzed them separately, the risk of malignancy for a CFO sample was 4% (9). The risk of malignancy for ND/UNS (not including CFO) was 1–4% (8–10).

A repeat aspiration with ultrasound guidance is recommended for ND/UNS and clinically/sonographically worrisome CFO cases and is diagnostic in 50–88% of the cases (2,6,9,11,13,14), but some nodules remain persistently ND/UNS. Excision is considered for persistently ND/UNS nodules because about 10% prove to be malignant (13).

Unless specified as ND/UNS, the FNA is considered adequate for evaluation. An explicit statement of adequacy is optional.

Benign

The benefit of thyroid FNA derives in large part from the ability to make a reliably benign interpretation that avoids unnecessary surgery. A “BENIGN” result is obtained in 60–70% of the thyroid FNAs. Descriptive comments that follow are used to subclassify the benign interpretation. The term “benign follicular nodule (BFN)” applies to the most common benign pattern: an adequately cellular specimen comprised of varying proportions of colloid and benign follicular cells arranged as macrofollicles and macrofollicle fragments. If resected, virtually all BFNs turn out to be either nodules of a multinodular goiter or follicular adenomas (FAs). This distinction cannot be made by FNA and is of no consequence to the patient. The false-negative rate of a benign interpretation is low (0–3%) (2,12), but patients are nevertheless followed with repeat assessment by palpation or ultrasound at 6–18 month intervals (15). If the nodule shows significant growth or suspicious sonographic changes, a repeat FNA is considered.

Other benign subcategories include “consistent with lymphocytic (Hashimoto) thyroiditis in the proper clinical context” and “consistent with granulomatous (subacute) thyroiditis.” This is a partial list and does not include a variety of other benign conditions like infections and amyloid goiter that are occasionally sampled by FNA. Additional benign findings (e.g., black thyroid, reactive changes, radiation changes, and cyst-lining cells) can be mentioned as descriptive diagnoses at the discretion of the cytopathologist.

Atypia of undetermined significance or Follicular lesion of undetermined significance

Some thyroid FNAs are not easily classified into the benign, suspicious, or malignant categories. Such cases represent a minority of thyroid FNAs and in the Bethesda System are reported as “Atypia of Undetermined Significance (AUS)” or “Follicular Lesion of Undetermined Significance.” The necessity for this category was debated at the NCI conference, after which a vote (limited to the clinicians in attendance) was taken, and the majority voted in favor of this category.

The heterogeneity of this category precludes outlining all scenarios for which an AUS interpretation is appropriate. The most common scenarios can be described as follows:

- A. There is a prominent population of microfollicles in an aspirate that does not otherwise fulfill the criteria for "Follicular Neoplasm/Suspicious for Follicular Neoplasm." This situation may arise when a predominance of microfollicles are seen in a sparsely cellular aspirate with scant colloid. Alternatively, a more prominent than usual population of microfollicles may occur (and may be disproportionately apparent on a minority of smears) in a moderately or markedly cellular sample, but the overall proportion of microfollicles is not sufficient for the diagnosis of "Follicular Neoplasm/Suspicious for Follicular Neoplasm."
- B. There is a predominance of Hürthle cells in a sparsely cellular aspirate with scant colloid.
- C. The interpretation of follicular cell atypia is hindered by sample preparation artifact, for example,
 - a. air-drying artifact with slight nuclear and cytoplasmic enlargement, pale and slightly smudgy chromatin, and/or mildly irregular nuclear contours,
 - b. clotting artifact with crowding.
- D. A moderately or markedly cellular sample is composed of a virtually exclusive population of Hürthle cells, yet the clinical setting suggests a benign Hürthle cell nodule, for example,
 - a. lymphocytic (Hashimoto) thyroiditis,
 - b. multinodular goiter
- E. There are focal features suggestive of papillary carcinoma, including nuclear grooves, enlarged nuclei with pale chromatin, and alterations in nuclear contour and shape in an otherwise predominantly benign-appearing sample (especially in patients with Hashimoto thyroiditis or those with abundant colloid and other benign-appearing follicular cells).
- F. There are cyst-lining cells that may appear atypical due to the presence of nuclear grooves, prominent nucleoli, elongated nuclei and cytoplasm, and/or intranuclear cytoplasmic inclusions in an otherwise predominantly benign-appearing sample (16).
- G. A minor population of follicular cells show nuclear enlargement, often accompanied by prominent nucleoli, for example,
 - a. specimens from patients with history of radioactive iodine, carbimazole, or other pharmaceutical agents,
 - b. repair due to involutional changes such as cystic degeneration and or hemorrhage
- H. There is an atypical lymphoid infiltrate (in which a repeat aspirate for flow cytometry is desirable), but the degree of atypia is insufficient for the general category "suspicious for malignancy."
- I. Not otherwise categorized.

Importantly, only nodules with atypia of undetermined significance should be placed in the AUS category. Recognizably benign cellular changes (e.g., typical cyst-lining cells, focal Hürthle cell change, changes ascribed to radioiodine therapy, and black thyroid) should not be interpreted as AUS. A moderately or even highly cellular specimen by itself (without significant nuclear or architectural atypia) does not qualify a nodule for an AUS interpretation.

An AUS result is obtained in 3–6% of thyroid FNAs (2,10). Higher rates likely represent an overuse of this category when other interpretations are more appropriate. The recommended management is clinical correlation and a repeat FNA at an appropriate interval (2,15). In most cases, a repeat FNA results in a more definitive interpretation; only about 20% of the nodules are repeatedly AUS (2). In some cases, however, the physician may choose not to repeat the FNA but follow the nodule clinically, or, alternatively, to refer the patient for surgery because of concerning clinical and/or sonographic features.

The risk of malignancy for an AUS nodule is difficult to ascertain because only a minority of cases in this category have surgical follow-up. Those that are resected represent a selected population of patients with repeatedly AUS results or patients with worrisome clinical or sonographic findings. In this selected population, 20–25% of the patients with AUS prove to have cancer after surgery, but this is undoubtedly an overestimate of the risk for all AUS interpretations (2,10). The risk of malignancy is certainly lower and probably closer to 5–15%. An effort should be made to use this category as a last resort and limit its use to approximately 7% or fewer of all thyroid FNAs.

Follicular neoplasm or Suspicious for a follicular neoplasm

The purpose of this diagnostic category is to identify a nodule that might be a follicular carcinoma (FC) and triage it for surgical lobectomy. FNA is diagnostic of many thyroid conditions (e.g., papillary carcinoma and lymphocytic thyroiditis), but, with regard to FC, it is better considered a screening test. FCs have cytomorphologic features that distinguish them from BFNs. Although these cytomorphologic features do not permit distinction from FA, they are reportable as "FOLLICULAR NEOPLASM" or "SUSPICIOUS FOR A FOLLICULAR NEOPLASM", leading to a definitive diagnostic procedure, usually lobectomy (12,15,17). The term "suspicious for a follicular neoplasm" is preferred by some laboratories over "follicular neoplasm" for this category because a significant proportion of cases (up to 35%) prove not to be neoplasms but rather hyperplastic proliferations of follicular cells, most commonly those of multinodular goiter (10,18–21). About 15–30% of the cases called FN/SFN prove to be malignant (2,10,19,22). The majority of SFN cases turn out to be FAs or adenomatoid nodules of multinodular goiter, both of which are more common than FC. Of those that prove to be malignant, many are FCs, but a significant proportion are follicular variants of papillary carcinoma (2,8,11,19).

Cytologic preparations typically have high cellularity, and colloid is scant or absent. The hallmark of this diagnostic category is a disturbed cytoarchitecture: follicular cells are arranged predominantly in microfollicular or trabecular arrangements. Cases that demonstrate the nuclear features of papillary carcinoma are excluded from this category. Cellular crowding and overlapping are conspicuous, and the follicular cells are usually larger than normal. Nuclear atypia/pleomorphism and mitoses are uncommon. A minor population of macrofollicles (intact spheres and fragments) can be present. Conspicuous cellularity alone does not qualify the nodule for a "suspicious" interpretation (23). If the sample is cellular but mostly macrofollicular (intact spheres and flat

fragments of evenly spaced follicular cells), a benign interpretation is appropriate. BFNs often have a small population of microfollicles and crowded groups. If these comprise the minority of the follicular cells, they have little significance and the FNA can be interpreted as benign. A suspicious interpretation is rendered only when the majority of the follicular cells are arranged in abnormal architectural groupings (microfollicles, crowded trabeculae).

The general category FN/SFN is a self-sufficient interpretation; narrative comments that follow are optional.

In the World Health Organization classification, Hürthle cell adenoma and Hürthle cell carcinoma (HC) are considered oncocytic variants of FA and FC, respectively (24). Studies suggest, however, that follicular and Hürthle cell tumors have different underlying genetics (4,25). For this reason, and because they have such distinctive morphologic features, it is helpful to specify that a sample raises the possibility of a Hürthle cell rather than a FN. This interpretation applies to cellular samples that are composed exclusively (or almost exclusively) of Hürthle cells. Oncocytic cells with nuclear features of papillary carcinoma are excluded from this interpretation. A significant proportion of these cases (16–25%) prove not to be neoplasms but rather hyperplastic proliferations of Hürthle cells in nodular goiter or lymphocytic thyroiditis (26,27). About 15–45% nodules are malignant, and the remainder of the neoplasms prove to be Hürthle cell adenomas (22,26,27).

Suspicious for malignancy

Many thyroid cancers, most especially papillary thyroid carcinoma (PTC), can be diagnosed with certainty by FNA. But the nuclear and architectural changes of some PTCs are subtle and focal. This is particularly true of the follicular variant of PTC, which can be difficult to distinguish from a BFN (28). Other PTCs may be incompletely sampled and yield only a small number of abnormal cells (29). If only one or two characteristic features of PTC are present, if they are only focal and not widespread throughout the follicular cell population, or if the sample is sparsely cellular, a malignant diagnosis cannot be made with certainty. Such cases occur with some regularity, and they are best classified as “SUSPICIOUS FOR MALIGNANCY,” qualified as “Suspicious for papillary carcinoma.” Nodules called suspicious for papillary carcinoma are resected, either by lobectomy or thyroidectomy. Most (60–75%) prove to be papillary carcinomas and the rest are usually FAs (2,10,12,30).

The same general principle applies to other thyroid malignancies like medullary carcinoma and lymphoma, but these are encountered less frequently than PTC. Ancillary testing (e.g., immunohistochemistry and flow cytometry) in borderline cases is usually more helpful with medullary carcinoma and lymphoma than PTC.

Malignant

The general category “MALIGNANT” is used whenever the cytomorphologic features are conclusive for malignancy. Descriptive comments that follow are used to subclassify the malignancy and summarize the results of special studies, if any. Approximately 3–7% of the thyroid FNAs have conclusive features of malignancy, and most are papillary carcinomas (2,10–12). Malignant nodules are usually removed by

thyroidectomy, with some exceptions (e.g., metastatic tumors, non-Hodgkin lymphomas, and undifferentiated carcinomas). The positive predictive value of a malignant FNA interpretation is 97–99%.

Summary

This document summarizes several years of work, begun as a Web-based discussion, followed by a live conference, and culminating in the production of a print and online atlas. It is the hope of all the contributors to this project that this terminology proposal will be a valuable first step toward uniformity and consensus in the reporting of thyroid FNA interpretations. As with the Bethesda System for cervical cytology, it is expected that subsequent workshops will lead to further refinements to this framework.

List of Bethesda Thyroid Atlas Contributors

- Pedro Patricio de Agustin, M.D., Ph.D.*, Department of Pathology, University Hospital “12 de Octubre,” Madrid, Spain
Erik K. Alexander, M.D., Department of Medicine, Brigham and Women’s Hospital, Boston, MA
Sylvia L. Asa, M.D., Ph.D., Department of Pathology and Laboratory Medicine, University of Toronto; University Health Network and Toronto Medical Laboratories; Ontario Cancer Institute, Toronto, Ontario, Canada
Kristen A. Atkins, M.D., Department of Pathology, University of Virginia Health System, Charlottesville, VA
Manon Auger, M.D., Department of Pathology, McGill University Health Center and McGill University, Montreal, Quebec, Canada
Zubair W. Baloch, M.D., Ph.D., Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, PA
Katherine Berezowski, M.D., Department of Pathology, Virginia Hospital Center, Arlington, VA
Massimo Bongiovanni, M.D., Department of Pathology, Geneva University Hospital, Geneva, Switzerland
Douglas P. Clark, M.D., Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD
Béatrix Cochand-Priollet, M.D., Ph.D., Department of Pathology, Lariboisière Hospital, University of Paris 7, Paris, France
Barbara A. Crothers, D.O., Department of Pathology, Walter Reed Army Medical Center, Springfield, VA
Richard M. DeMay, M.D., Department of Pathology, University of Chicago, Chicago, IL
Tarik M. Elsheikh, M.D., Ball Memorial Hospital/PA Labs, Muncie, IN
William C. Faquin, M.D., Ph.D., Department of Pathology, Massachusetts General Hospital, Boston, MA
Armando C. Filie, M.D., Laboratory of Pathology, National Cancer Institute, Bethesda, MD
Pinar Firat, M.D., Department of Pathology, Hacettepe University, Ankara, Turkey
William J. Frable, M.D., Department of Pathology, Medical College of Virginia Hospitals, Virginia Commonwealth University Medical Center, Richmond, VA
Kim R. Geisinger, M.D., Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC
Hossein Gharib, M.D., Department of Endocrinology, Mayo Clinic College of Medicine, Rochester, MN
Ulrike M. Hamper, M.D., Department of Radiology and Radiological Sciences, The Johns Hopkins Medical Institutions, Baltimore, MD

- Michael R. Henry, M.D., Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN
- Jeffrey F. Krane, M.D., Ph.D., Department of Pathology, Brigham and Women's Hospital, Boston, MA
- Lester J. Layfield, M.D., Department of Pathology, University of Utah Hospital and Clinics, Salt Lake City, UT
- Virginia A. LiVolsi, M.D., Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, PA
- Britt-Marie E. Ljung, M.D., Department of Pathology, University of California San Francisco, San Francisco, CA
- Claire W. Michael, M.D., Department of Pathology, University of Michigan Medical Center, Ann Arbor, MI
- Ritu Nayar, M.D., Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL
- Yolanda C. Oertel, M.D., Department of Pathology, Washington Hospital Center, Washington, DC
- Martha B. Pitman, M.D., Department of Pathology, Massachusetts General Hospital, Boston, MA
- Celeste N. Powers, M.D., Ph.D., Department of Pathology, Medical College of Virginia Hospitals, Virginia Commonwealth University Medical Center, Richmond, VA
- Stephen S. Raab, M.D., Department of Pathology, University of Colorado at Denver, UCDHSC Anschutz Medical Campus, Aurora, CO
- Andrew A. Renshaw, M.D., Department of Pathology, Baptist Hospital of Miami, Miami, FL
- Juan Rosai, M.D., Dipartimento di Patologia, Istituto Nazionale Tumori, Milano, Italy
- Miguel A. Sanchez, M.D., Department of Pathology, Englewood Hospital and Medical Center, Englewood, NJ
- Vinod Shidham, M.D., Department of Pathology, Medical College of Wisconsin, Milwaukee, WI
- Mary K. Sidawy, M.D., Department of Pathology, Georgetown University Medical Center, Washington, DC
- Gregg A. Staerckel, M.D., Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
- Edward B. Stelow, M.D., Department of Pathology, University of Virginia Health System, Charlottesville, VA
- Jerry Waisman, M.D., Department of Pathology, New York University of Medicine, New York, NY
- Helen H. Wang, M.D., Dr.P.H., Department of Pathology, Beth Israel-Deaconess Medical Center, Boston, MA
- Philippe Vielh, M.D., Ph.D., Department of Pathology, Institut de Cancerologie Gustave Roussy, France
- Grace C. H. Yang, M.D., Department of Pathology, Weill Medical College of Cornell University, New York, NY
- Matthew A. Zarka, M.D., Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, AZ
- nodules. Impact on thyroid practice and cost of care. *Am J Med* **73**:381–384.
2. Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, Moore FD Jr., Kim BW, Nose V, Marqusee E, Larsen PR, Alexander EK 2007 Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. *Cancer* **111**:508–516.
 3. Ali SZ, Cibas ES (eds) 2009 *The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes*. Springer, New York.
 4. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ 2008 Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. *Diagn Cytopathol* **36**:425–437.
 5. Baloch ZW, Cibas ES, Clark DP, Layfield LJ, Ljung BM, Pitman MB, Abati A 2008 *The National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference: a summation*. *CytoJournal* **5**:6.
 6. Goellner JR, Gharib H, Grant CS, Johnson DA 1987 Fine-needle aspiration cytology of the thyroid, 1980 to 1986. *Acta Cytol* **31**:587–590.
 7. Grant CS, Hay ID, Gough IR, McCarthy PM, Goellner JR 1989 Long-term follow-up of patients with benign thyroid fine-needle aspiration cytologic diagnoses. *Surgery* **106**:980–985.
 8. Ravetto C, Colombo L, Dottorini ME 2000 Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. *Cancer* **90**:357–363.
 9. Renshaw AA 2001 Accuracy of thyroid fine-needle aspiration using receiver operator characteristic curves. *Am J Clin Pathol* **116**:477–482.
 10. Yang J, Schnadig V, Logrono R, Wasserman PG 2007 Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. *Cancer* **111**:306–315.
 11. Amrikachi M, Ramzy I, Rubinfeld S, Wheeler TM 2001 Accuracy of fine-needle aspiration of thyroid: a review of 6226 cases and correlation with surgical or clinical outcome. *Arch Pathol Lab Med* **125**:484–488.
 12. Gharib H, Goellner JR, Johnson DA 1993 Fine-needle aspiration cytology of the thyroid: a 12-year experience with 11,000 biopsies. *Clin Lab Med* **13**:699–709.
 13. McHenry CR, Walfish PG, Rosen IB 1993 Non-diagnostic fine-needle aspiration biopsy: a dilemma in management of nodular thyroid disease. *Am Surg* **59**:415–419.
 14. van Hoeven KH, Gupta PK, LiVolsi VA 1994 Value of repeat fine needle aspiration (FNA) of the thyroid [Abstract]. *Mod Pathol* **7**:43A, abstract no. 233.
 15. Layfield L, Cochand-Priollet B, LiVolsi V, Abrams J, Merino M, Gharib H, Greenspan F, Wells S, Evans D, Henry M, Wang HH 2008 Post thyroid FNA testing and treatment options: a synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. *Diagn Cytopathol* **36**:442–448.
 16. Faquin WC, Cibas ES, Renshaw AA 2005 "Atypical" cells in fine-needle aspiration biopsy specimens of benign thyroid cysts. *Cancer* **105**:71–79.
 17. Mazzaferri EL 1999 NCCN thyroid carcinoma practice guidelines. *Oncology* **13**:391–442.
 18. Deveci MS, Deveci G, LiVolsi VA, Baloch ZW 2006 Fine-needle aspiration of follicular lesions of the thyroid. *Diagnosis and follow-up*. *CytoJournal* **3**:9.

Acknowledgment

The authors thank Dr. Diane Solomon for her review of the manuscript and helpful comments.

Disclosure Statement

The authors declare that no competing financial interests exist.

References

1. Hamberger B, Gharib H, Melton LJ, 3rd, Goellner JR, Zinsmeister AR 1982 Fine-needle aspiration biopsy of thyroid

19. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK 2002 Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. *Diagn Cytopathol* **26**:41–44.
20. Schlinkert RT, van Heerden JA, Goellner JR, Gharib H, Smith SL, Rosales RF, Weaver AL 1997 Factors that predict malignant thyroid lesions when fine-needle aspiration is "suspicious for follicular neoplasm". *Mayo Clin Proc* **72**:913–916.
21. Kelman AS, Rathan A, Leibowitz J, Burstein DE, Haber RS 2001 Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens. *Thyroid* **11**:271–277.
22. Gharib H, Goellner JR 1993 Fine-needle aspiration biopsy of the thyroid: an appraisal. *Ann Int Med* **118**:282–289.
23. Suen KC 1988 How does one separate cellular follicular lesions of the thyroid by fine-needle aspiration biopsy? *Diagn Cytopathol* **4**:78–81.
24. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) 2004 World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press, Lyon.
25. French CA, Alexander EK, Cibas ES, Nose V, Laguette J, Faquin W, Garber J, Moore F Jr., Fletcher JA, Larsen PR, Kroll TG 2003 Genetic and biological subgroups of low-stage follicular thyroid cancer. *Am J Pathol* **162**:1053–1060.
26. Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW 2006 Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? *Diagn Cytopathol* **34**:330–334.
27. Giorgadze T, Rossi ED, Fadda G, Gupta PK, Livolsi VA, Baloch Z 2004 Does the fine-needle aspiration diagnosis of "Hurthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy? *Diagn Cytopathol* **31**:307–312.
28. Chung D, Ghossein RA, Lin O 2007 Macrofollicular variant of papillary carcinoma: a potential thyroid FNA pitfall. *Diagn Cytopathol* **35**:560–564.
29. Renshaw AA 2002 Focal features of papillary carcinoma of the thyroid in fine-needle aspiration material are strongly associated with papillary carcinoma at resection. *Am J Clin Pathol* **118**:208–210.
30. Logani S, Gupta PK, LiVolsi VA, Mandel S, Baloch ZW 2000 Thyroid nodules with FNA cytology suspicious for follicular variant of papillary thyroid carcinoma: follow-up and management. *Diagn Cytopathol* **23**:380–385.

Address correspondence to:
Edmund S. Cibas, M.D.
Department of Pathology
Brigham and Women's Hospital
75 Francis St.
Boston, MA 02115

E-mail: ecibas@partners.org

This article has been cited by:

1. Michael Heller, Kyle Zanocco, Sara Zydowicz, Dina Elaraj, Ritu Nayar, Cord Sturgeon. 2012. Cost-effectiveness analysis of repeat fine-needle aspiration for thyroid biopsies read as atypia of undetermined significance. *Surgery* **152**:3, 423-430. [[CrossRef](#)]
2. Sushruta S. Nagarkatti, William C. Faquin, Carrie C. Lubitz, Dieter Morales Garcia, Giuseppe Barbesino, Douglas S. Ross, Richard A. Hodin, Gilbert H. Daniels, Sareh Parangi. 2012. Management of Thyroid Nodules with Atypical Cytology on Fine-needle Aspiration Biopsy. *Annals of Surgical Oncology* . [[CrossRef](#)]
3. Dr. Ogechukwu P. Eze , Dr. Guoping Cai , Dr. Zubair W. Baloch , Dr. Ashraf Khan , Dr. Renu Virk , Dr. Lynwood Hammers , Dr. Robert Udelsman , Dr. Sanziana Roman , Dr. Julie Ann Sosa , Dr. Tobias Carling , Dr. David C Chhieng , Dr. Constantine G. A. Theoharis , Dr. Manju L. Prasad . Vanishing Thyroid Tumors: A Diagnostic Dilemma Following Ultrasound Guided Fine Needle Aspiration. *Thyroid* **0**:ja. . [[Abstract](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
4. Dhafir Al-azawi, G. Bruce Mann, Rodney T. Judson, Julie A. Miller. 2012. Endocrine Surgeon-Performed US Guided Thyroid FNAC is Accurate and Efficient. *World Journal of Surgery* **36**:8, 1947-1952. [[CrossRef](#)]
5. Yoon Seong Choi, Soon Won Hong, Jin Young Kwak, Hee Jung Moon, Eun-Kyung Kim. 2012. Clinical and Ultrasonographic Findings Affecting Nondiagnostic Results upon the Second Fine Needle Aspiration for Thyroid Nodules. *Annals of Surgical Oncology* **19**:7, 2304-2309. [[CrossRef](#)]
6. Daniel S. Duick. 2012. Overview of Molecular Biomarkers for Enhancing the Management of Cytologically Indeterminate Thyroid Nodules and Thyroid Cancer. *Endocrine Practice* **18**:4, 611-615. [[CrossRef](#)]
7. Carrie C. Lubitz , Sushruta S. Nagarkatti , William C. Faquin , Anthony E. Samir , Maria C. Hassan , Giuseppe Barbesino , Douglas S. Ross , Gregory W. Randolph , Randall D. Gaz , Antonia E. Stephen , Richard A. Hodin , Gilbert H. Daniels , Sareh Parangi . 2012. Diagnostic Yield of Nondiagnostic Thyroid Nodules Is Not Altered by Timing of Repeat Biopsy. *Thyroid* **22**:6, 590-594. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
8. E.A. Sinna, N. Ezzat. 2012. Diagnostic accuracy of fine needle aspiration cytology in thyroid lesions. *Journal of the Egyptian National Cancer Institute* **24**:2, 63-70. [[CrossRef](#)]
9. Frédérique Albarel, Bernard Conte-Devolx, Charles Oliver. 2012. From nodule to differentiated thyroid carcinoma: Contributions of molecular analysis in 2012. *Annales d'Endocrinologie* **73**:3, 155-164. [[CrossRef](#)]
10. Dong Gyu Na , Ji-hoon Kim , Jin Yong Sung , Jung Hwan Baek , Kyeong Cheon Jung , Hunkyung Lee , Hyunju Yoo . 2012. Core-Needle Biopsy Is More Useful Than Repeat Fine-Needle Aspiration in Thyroid Nodules Read as Nondiagnostic or Atypia of Undetermined Significance by the Bethesda System for Reporting Thyroid Cytopathology. *Thyroid* **22**:5, 468-475. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental material](#)]
11. Justin L. Seningen, Aziza Nassar, Michael R. Henry, Zubair Baloch. 2012. Correlation of thyroid nodule fine-needle aspiration cytology with corresponding histology at Mayo Clinic, 2001-2007: An institutional experience of 1,945 cases. *Diagnostic Cytopathology* **40**:S1, E27-E32. [[CrossRef](#)]
12. Haggi Mazeh, Yair Levy, Ido Mizrahi, Liat Appelbaum, Nadia Ilyayev, David Halle, Herbert R. Freund, Aviram Nissan. 2012. Differentiating benign from malignant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy. *Journal of Surgical Research* . [[CrossRef](#)]
13. Thomas J. Sebo. 2012. Thyroid Fine Needle Aspiration Cytology: Nothing New Except a Re-Emphasis on A Back-To-Basics and Cost-Effective Approach to Interpretation in the Era of Ultrasound Examination and Molecular Diagnostics. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
14. Jin Yong Sung, Dong Gyu Na, Kyu Sun Kim, Hyunju Yoo, Hunkyung Lee, Ji-hoon Kim, Jung Hwan Baek. 2012. Diagnostic accuracy of fine-needle aspiration versus core-needle biopsy for the diagnosis of thyroid malignancy in a clinical cohort. *European Radiology* . [[CrossRef](#)]
15. Toni Beninato , David A. Kleiman , Theresa Scognamiglio , Thomas J. Fahey III , Rasa Zarnegar . 2012. Tract Recurrence of a Follicular Thyroid Neoplasm Following Transaxillary Endoscopic Thyroidectomy. *Thyroid* **22**:2, 214-217. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
16. Rulong Shen , Sandya Liyanarachchi , Wei Li , Paul E. Wakely Jr. , Motoyasu Saji , Jie Huang , Rebecca Nagy , Tisha Farrell , Matthew D. Ringel , Albert de la Chapelle , Richard T. Kloos , Huiling He . 2012. MicroRNA Signature in Thyroid Fine Needle Aspiration Cytology Applied to "Atypia of Undetermined Significance" Cases. *Thyroid* **22**:1, 9-16. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental material](#)]
17. Kevin Hudak, Haggi Mazeh, Rebecca S. Sippel, Herbert Chen. 2012. Hürthle cell metaplasia on fine-needle aspiration biopsy is not by itself an indication for thyroid surgery. *The American Journal of Surgery* . [[CrossRef](#)]

18. Lewis D. Hahn, Clifford Hoyt, David L. Rimm, Constantine Theoharis. 2012. Spatial spectral imaging as an adjunct to the Bethesda classification of thyroid fine-needle aspiration specimens. *Cancer Cytopathology* n/a-n/a. [[CrossRef](#)]
19. Eun Kyung Lee, Ki-Wook Chung, Hye Sook Min, Tae Sung Kim, Tae Hyun Kim, Jun Sun Ryu, Yoo Seok Jung, Seok Ki Kim, You Jin Lee. 2012. Preoperative Serum Thyroglobulin as a Useful Predictive Marker to Differentiate Follicular Thyroid Cancer from Benign Nodules in Indeterminate Nodules. *Journal of Korean Medical Science* **27**:9, 1014. [[CrossRef](#)]
20. Jee Hee Yoon, Hee Kyung Kim, Soo Jeong Kim, Jin Seong Cho, Ho-Cheol Kang. 2012. Prevalence of Thyroid Cancer in Thyroid Nodules with Dense Calcification. *Korean Journal of Medicine* **83**:3, 322. [[CrossRef](#)]
21. Roberto Izquierdo, Rohini Kasturi, Kamal Khurana, Rachel Hopkins, Ismatun Swati. 2012. Feasibility of immediate assessment of fine needle aspirates of thyroid nodules by telecytopathology. *Endocrine Practice* **1**:-1, 1-20. [[CrossRef](#)]
22. James T. Broome, Carmen C. Solorzano. 2011. The impact of atypia/follicular lesion of undetermined significance on the rate of malignancy in thyroid fine-needle aspiration: Evaluation of the Bethesda System for Reporting Thyroid Cytopathology. *Surgery* **150**:6, 1234-1241. [[CrossRef](#)]
23. Andrew A. Renshaw. 2011. Quality Improvement in Cytology: Where Do We Go From Here?. *Archives of Pathology & Laboratory Medicine* **135**:11, 1387-1390. [[CrossRef](#)]
24. M. Regina Castro , Rachel P. Espiritu , Rebecca S. Bahn , Michael R. Henry , Hossein Gharib , Pedro J. Caraballo , John C. Morris . 2011. Predictors of Malignancy in Patients with Cytologically Suspicious Thyroid Nodules. *Thyroid* **21**:11, 1191-1198. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
25. Jung Hyun Yoon, Eun-Kyung Kim, Eun Ju Son, Hee Jung Moon, Jin Young Kwak. 2011. Diffuse Microcalcifications Only of the Thyroid Gland Seen on Ultrasound: Clinical Implication and Diagnostic Approach. *Annals of Surgical Oncology* **18**:10, 2899-2906. [[CrossRef](#)]
26. Beatrix Cochand-Priollet , Henri Dahan , Marie Laloi-Michelin , Marc Polivka , Michele Saada , Philippe Herman , Pierre-Jean Guillausseau , Lounis Hamzi , Nicolas Poté , Emile Sarfati , Michel Wassef , Herve Combe , Danielle Raulic-Raimond , Pierre Chedin , Virginie Medeau , Daniele Casanova , Romain Kania . 2011. Immunocytochemistry with Cytokeratin 19 and Anti-Human Mesothelial Cell Antibody (HBME1) Increases the Diagnostic Accuracy of Thyroid Fine-Needle Aspirations: Preliminary Report of 150 Liquid-Based Fine-Needle Aspirations with Histological Control. *Thyroid* **21**:10, 1067-1073. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
27. Jung Hyun Yoon , Jin Young Kwak , Hee Jung Moon , Min Jung Kim , Eun-Kyung Kim . 2011. The Diagnostic Accuracy of Ultrasound-Guided Fine-Needle Aspiration Biopsy and the Sonographic Differences Between Benign and Malignant Thyroid Nodules 3 cm or Larger. *Thyroid* **21**:9, 993-1000. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
28. Seon Hyeong Choi, Kyung Hwa Han, Jung Hyun Yoon, Hee Jung Moon, Eun Ju Son, Ji Hyun Youk, Eun-Kyung Kim, Jin Young Kwak. 2011. Factors affecting inadequate sampling of ultrasound-guided fine-needle aspiration biopsy of thyroid nodules. *Clinical Endocrinology* **74**:6, 776-782. [[CrossRef](#)]
29. Gianna Carla Alberti Schrut, Fabíola Yukiko Miasaki, Gilberto Paz-Filho, Teresa Cristina Santos Cavalcanti, Hans Graf, Gisah Amaral Carvalho. 2011. Changes Associated with Percutaneous Ethanol Injection in the Treatment of Thyroid Nodules. *Endocrine Pathology* **22**:2, 79-85. [[CrossRef](#)]
30. Jung Hyun Yoon, Hee Jung Moon, Eun-Kyung Kim, Jin Young Kwak. 2011. Inadequate Cytology in Thyroid Nodules: Should We Repeat Aspiration or Follow-Up?. *Annals of Surgical Oncology* **18**:5, 1282-1289. [[CrossRef](#)]
31. James H. Wood, David A. Partrick, Henry P. Barham, Denis D. Bensard, Sharon H. Travers, Jennifer L. Bruny, Robert C. McIntyre. 2011. Pediatric thyroidectomy: a collaborative surgical approach. *Journal of Pediatric Surgery* **46**:5, 823-828. [[CrossRef](#)]
32. Amy E. Cox, Shane O. LeBeau. 2011. Diagnosis and Treatment of Differentiated Thyroid Carcinoma. *Radiologic Clinics of North America* **49**:3, 453-462. [[CrossRef](#)]
33. Chung-Che Charles Wang , Lyssa Friedman , Giulia C. Kennedy , Hui Wang , Electron Kebebew , David L. Steward , Martha A. Zeiger , William H. Westra , Yongchun Wang , Elham Khanafshar , Giovanni Fellegara , Juan Rosai , Virginia LiVolsi , Richard B. Lanman . 2011. A Large Multicenter Correlation Study of Thyroid Nodule Cytopathology and Histopathology. *Thyroid* **21**:3, 243-251. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
34. Charles H. Emerson . 2011. Can Thyroid Ultrasound and Related Procedures Provide Diagnostic Information About Thyroid Nodules: A Look at the Guidelines. *Thyroid* **21**:3, 211-213. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
35. M. Sellami, S. Tababi, J. Mamy, R. Zainine, A. Charfi, N. Beltaief, S. Sahtout, G. Besbes. 2011. Interest of fine-needle aspiration cytology in thyroid nodule. *European Annals of Otorhinolaryngology, Head and Neck Diseases* . [[CrossRef](#)]

36. Stefan Scholz, Jessica R. Smith, Beverly Chaignaud, Robert C. Shamberger, Stephen A. Huang. 2011. Thyroid surgery at Children's Hospital Boston: a 35-year single-institution experience. *Journal of Pediatric Surgery* **46**:3, 437-442. [[CrossRef](#)]
37. José Miguel Domínguez, René Baudrand, Jaime Cerda, Claudia Campusano, Carlos Fardella, Eugenio Arteaga, Francisco Cruz, Antonieta Solar, Tatiana Arias, Lorena Mosso. 2011. An Ultrasound Model to Discriminate the Risk of Thyroid Carcinoma. *Academic Radiology* **18**:2, 242-245. [[CrossRef](#)]
38. Seong Yong Ahn, Yeon Hee Joo, Jin Pyeong Kim, Seung Hoon Woo. 2011. A Case of Minimal Invasive Follicular Carcinoma in Childhood. *Korean Journal of Otorhinolaryngology-Head and Neck Surgery* **54**:1, 69. [[CrossRef](#)]
39. Won-Jin Moon, Jung Hwan Baek, So Lyung Jung, Dong Wook Kim, Eun Kyung Kim, Ji Young Kim, Jin Young Kwak, Jeong Hyun Lee, Joon Hyung Lee, Young Hen Lee, Dong Gyu Na, Jeong Seon Park, Sun Won Park. 2011. Ultrasonography and the Ultrasound-Based Management of Thyroid Nodules: Consensus Statement and Recommendations. *Korean Journal of Radiology* **12**:1, 1. [[CrossRef](#)]
40. Yul Hwang Bo, Hwa Young Ahn, Yun Hee Lee, Ye Jin Lee, Jung Hee Kim, Jung Hun Ohn, Eun Shil Hong, Kyung Won Kim, In Kyung Jeong, Sung Hee Choi, Soo Lim, Do Joon Park, Hak Chul Jang, Byung-Hee Oh, Bo Youn Cho, Young Joo Park. 2011. Malignancy Rate in Sonographically Suspicious Thyroid Nodules of Less than a Centimeter in Size Does Not Decrease with Decreasing Size. *Journal of Korean Medical Science* **26**:2, 237. [[CrossRef](#)]
41. Yoo Seung Chung, Changyoung Yoo, Ji Han Jung, Hyun Joo Choi, Young-Jin Suh. 2011. Review of atypical cytology of thyroid nodule according to the Bethesda system and its beneficial effect in the surgical treatment of papillary carcinoma. *Journal of the Korean Surgical Society* **81**:2, 75. [[CrossRef](#)]
42. Matthew J. Horne, David C. Chhieng, Constantine Theoharis, Kevin Schofield, Diane Kowalski, Manju L. Prasad, Lynwood Hammers, Robert Udelsman, Adebowale J. Adeniran. 2011. Thyroid follicular lesion of undetermined significance: Evaluation of the risk of malignancy using the two-tier sub-classification. *Diagnostic Cytopathology* n/a-n/a. [[CrossRef](#)]
43. U. S. Tetikkurt, F. Oz Puyan, F. Oz, N. Erdogan, S. Ceylan, A. Yakupoglu. 2011. Diagnostic value of liquid-based (Liqui-PREP) preparations and interobserver reproducibility in fine needle aspiration cytology of the nodular thyroid lesions. *Diagnostic Cytopathology* n/a-n/a. [[CrossRef](#)]
44. Massimo Bongiovanni, Stefano Crippa, Zubair Baloch, Simonetta Piana, Alessandra Spitale, Fabio Pagni, Luca Mazzucchelli, Camillo Di Bella, William Faquin. 2011. Comparison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid cytopathology. *Cancer Cytopathology* n/a-n/a. [[CrossRef](#)]
45. Tomer Davidov, Stanley Z. Trooskin, Beth-Ann Shanker, Dana Yip, Oliver Eng, Jessica Crystal, Jun Hu, Victoriya S. Chernyavsky, Malik F. Deen, Michael May. 2010. Routine second-opinion cytopathology review of thyroid fine needle aspiration biopsies reduces diagnostic thyroidectomy. *Surgery* **148**:6, 1294-1301. [[CrossRef](#)]
46. Jennifer L. Rabaglia, Wareef Kabbani, Lucy Wallace, Shelby Holt, Lori Watumull, Jeffrey Pruitt, William H. Snyder, Fiemu E. Nwariaku. 2010. Effect of the Bethesda system for reporting thyroid cytopathology on thyroidectomy rates and malignancy risk in cytologically indeterminate lesions. *Surgery* **148**:6, 1267-1273. [[CrossRef](#)]
47. Agnese Proietti , Riccardo Giannini , Clara Ugolini , Mario Miccoli , Gabriella Fontanini , Giancarlo Di Coscio , Rossana Romani , Piero Berti , Paolo Miccoli , Fulvio Basolo . 2010. BRAF Status of Follicular Variant of Papillary Thyroid Carcinoma and its Relationship to Its Clinical and Cytological Features. *Thyroid* **20**:11, 1263-1270. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
48. Maurilio Deandrea , Federico Ragazzoni , Manuela Motta , Bruno Torchio , Alberto Mormile , Francesca Garino , Gabriella Magliona , Elena Gamarra , Maria Josefina Ramunni , Roberto Garberoglio , Paolo P. Limone . 2010. Diagnostic Value of a Cytomorphological Subclassification of Follicular Patterned Thyroid Lesions: A Study of 927 Consecutive Cases with Histological Correlation. *Thyroid* **20**:10, 1077-1083. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
49. L. J. Layfield, E. S. Cibas, Z. Baloch. 2010. Thyroid fine needle aspiration cytology: a review of the National Cancer Institute state of the science symposium. *Cytopathology* **21**:2, 75-85. [[CrossRef](#)]
50. G. Kocjan, B. Cochand-Priollet, P. P. de Agustin, C. Bourgain, A. Chandra, Y. Daneshbod, A. Deery, J. Duskova, C. Ersoz, G. Fadda, A. Fassina, P. Firat, B. Jimenez-Ayala, P. Karakitsos, O. Koperek, N. Matesa, D. Poller, L. Thienpont, A. Ryska, U. Schenck, T. Sauer, F. Schmitt, E. Tani, T. Toivonen, M. Tötsch, G. Troncone, L. Vass, P. Vielh. 2010. Diagnostic terminology for reporting thyroid fine needle aspiration cytology: European Federation of Cytology Societies thyroid working party symposium, Lisbon 2009. *Cytopathology* **21**:2, 86-92. [[CrossRef](#)]
51. Soo Kee Min, Jinwon Seo, Sun-Young Jun, Kwangseon Min, Hye-Rim Park. 2010. The Analysis of Indeterminate Category in Thyroid Fine Needle Aspiration. *The Korean Journal of Pathology* **44**:6, 657. [[CrossRef](#)]

52. Efisio Puxeddu , Sebastiano Filetti . 2009. The 2009 American Thyroid Association Guidelines for Management of Thyroid Nodules and Differentiated Thyroid Cancer: Progress on the Road from Consensus- to Evidence-Based Practice. *Thyroid* **19**:11, 1145-1147. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
53. Charles H. Emerson . 2009. Guidelines for Guidelines: Content, Accountability, Peer Review, and Intellectual Ownership. *Thyroid* **19**:11, 1137-1138. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]